Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis

European Journal of Clinical Pharmacology
Yi-Chia SuChih-Chien Wu

Abstract

Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. PubMed, the Cochrane library, and the ClinicalTrials.gov website were searched from inception until December 2017. Studies comparing reactivation in prophylaxis versus non-prophylaxis in patients undergoing immunosuppressive therapy or chemotherapy were included. The meta-analysis was performed to calculate the relative risk (RR) and the pooled estimates. A meta-analysis was conducted of 13 studies (2 randomized controlled trials [RCTs] and 11 cohort studies). The summary RR for HBV reactivation was 0.47 (95% confidence interval [CI] 0.13-1.69) for antiviral prophylaxis versus non-prophylaxis. Both of the RCTs included in the meta-analysis enrolled patients treated with rituximab. Subgroup analyses showed that the two RCTs ± high-quality cohort studies showed a decreased risk of HBV reactivation among the antiviral prophylaxi...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Winnie YeoPaul K S Chan
Oct 2, 2012·Journal of Gastroenterology and Hepatology·Winnie Yeo, Henry L Y Chan
Jun 19, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yi-Hsiang HuangShou-Dong Lee
Aug 6, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Seok Jin KimWon Seog Kim
Sep 5, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chiun HsuUNKNOWN Taiwan Cooperative Oncology Group
Oct 8, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wai-Kay SetoMan-Fung Yuen
Nov 22, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Adrian M Di BisceglieJay H Hoofnagle
Jan 24, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michele BaroneGiovanni Lapadula
Mar 20, 2015·JAMA : the Journal of the American Medical Association·Robert P PerrilloAnna S Lok
Jun 9, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Jeong-Ju YooYoon Jun Kim
Jun 1, 2012·Hepatology International·Yun-Fan LiawMasao Omata
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F LokKhaled Mohammed
Sep 24, 2016·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Yolanda Braun-MoscoviciAlexandra Balbir-Gurman
Sep 27, 2016·European Journal of Gastroenterology & Hepatology·Nikolaos PapadopoulosDimitrios Pectasides
Dec 28, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Wai-Kay SetoMan-Fung Yuen
Feb 25, 2017·Annals of Hepatology·Maria GuarinoFilomena Morisco

❮ Previous
Next ❯

Software Mentioned

Cochrane
Cochrane Risk of Bias
Review Manager

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.